HHS & Healthcare Contracts Intelligence — July 08, 2026

Leidos Holdings subsidiary secured a cost-plus-fixed-fee contract for operational tasks at NIH NCI, with options up to $139.9M. The award is full and open competition, not set aside, and runs through August 2027.

Cost-plus-fixed-fee contracts carry performance risk if costs overrun, though NIH NCI funding is stable. Leidos must manage operational tasks within budget to avoid margin pressure.

Leidos can leverage this NIH NCI award to expand its health R&D services footprint, potentially winning follow-on task orders or recompetes in the $400B+ federal health market.

The $77.6M award to Leidos Biomedical Research underscores continued NIH investment in life sciences R&D (NAICS 541715), a stable civilian sector with low budget volatility relative to defense.

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"Single $77.6M award reinforces its position in NIH NCI contracts; option exercise by August 2026 is a key catalyst.", "trigger"=>"Option year exercise announcement by August 2026; any modifications to the delivery order"}